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Abstract 
Purpose: To examine septin 9 gene-promoter methylation content in colorectal cancer and establish its 
significance in cancer progression and chemoresistance.  
Methods: Patient samples and colorectal cancer cell lines (CRC) were evaluated for septin 9 
expression and promoter hypermethylation content. Septin 9 promoter methylation and expression in 
cells were perturbed by 5-AZA (5-aza-2'-deoxycytidine) treatments or overexpression and probed for 
changes in Rho A signaling, cell proliferation, and migration.  Finally, the significance of septin 9 
methylation in chemoresistance was probed using apoptotic assays in CRC cells and in a xenograft 
tumor model.  
Results: Expression analysis showed a reduction in septin 9 levels in tumor tissues (p < 0.001) and cell 
lines (p < 0.01), while an increase in septin 9 promoter methylation was seen, respectively ( > 2-fold; p < 
0.01).  Increasing septin 9 levels in CRC cells by 5-AZA treatments or overexpression showed 
decreased Rho A signaling and cell migration (p < 0.01), whereas cell proliferation remained unaffected.  
Furthermore, increasing septin 9 levels also exhibited increased cisplatin-induced apoptosis in CRC 
cells and reduced chemoresistance in the mouse (~2-fold; p < 0. 01).   
Conclusion: Septin 9 promoter hypermethylation reduces septin 9 expression and promotes migration 
and chemoresistance. 
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Colorectal cancer (CRC) is one of the leading 
cancer types causing mortality worldwide [1]. 
Treatment options such as surgical resection, 
radiotherapy and chemotherapy are widely used 
but its outcomes are largely based on the stage 
of cancer [2,3].  The patients with stage I CRC 
exhibit 94.1 % five-year survival rate while it is 
significantly reduced to 24 % in stage IV disease 
[2,3]. Thus early detection of the cancer has a 
significant impact on the treatment outcome.  
 
Changes in DNA methylation profile of critical 
genes in cells is one of the early molecular 
changes in cancer progression [4,5]. These 
epigenetic events combined with disease-
causing mutations provide a selective advantage 
for cancer initiation and progression. Multiple 
studies have shown that septin 9 gene spanning 
a region of 219 kb in the genome and encoding 
different isoforms is epigenetically modified in the 
promoter region, and can be used as a 
diagnostic test for CRC [6-8].  
 
Recent studies have shown that septin 9 
promotes angiogenesis and facilitate tumor 
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growth in the hetero-transplant model [9].  In 
contrast, breast cancer-related studies have 
indicated distinct cellular functions and 
suggested a tumor-suppressor role [10]. Despite 
that, it remains unclear how septin 9 
hypermethylation affects gene expression in 
normal and neoplastic colon tissues and cells, 
and the underlying molecular mechanisms 
triggered due to aberrant septin 9 methylation in 
tumor development and chemoresistance, 




Cells and tissue samples 
 
SW480, CCD-18Co, HT-29, HS6751, HCT-116 
and LoVo cell lines were purchased from 
American Type Culture Collection (ATCC) and 
maintained as per the instructions provided.  For 
patient samples, colon neoplastic and adjacent 
non-transformed tissue samples were obtained 
from institute’s pathology archive following 
institutional review board approval from The 
People’s Hospital of Laiwu City, Laiwu, 
Shangdong (Protocol  no. 2705S).  Tissue 
samples were then processed accordingly for 
different procedures.  
 
Quantitative realtime polymerase chain 
reaction (qRT-PCR) 
 
Total RNA was extracted from cells and tissue 
samples using RNAeasy kit (Qiagen) and cDNA 
synthesis was performed as described previously 
[11]. Gene-specific PCR was performed CFX96 
Touch™ Real-Time PCR Detection System (Bio-
Rad, USA) using specific TaqMan probes and 
universal PCR Master Mix (Life Technologies, 
USA). The TaqMan probes used for analyzing 
the gene expressions were:  Septin 9- 
Hs00246396_m1; GAPDH -Hs02758991_g1 
(Applied Biosystems, USA)  
 
Pyrosequencing assays targeting Septin 9 
promoter regions 
 
DNA was extracted from cells and patient 
samples and evaluated for the status of 
methylation in CpG dinucleotides located in 
septin 9 promoter region.  We utilized the Qiagen 
PyroMark assay kit (Qiagen, USA) and  
investigated the methylation status as described 
previously [12 ] using the primer sets: Fwd: 
GATCTAGCCTAGGGTTCCAG, Rev: 
ACCGTTCGTGCAGACGAG (5’-biotin labeled) 
and the sequencing probe: 
TTGACGCGGTGCTAG. Briefly, the PCR 
products were suspended  using the PyroMark 
Q24 (Qiagen) following the manufacturer’s 
protocol, and the methylation status was 
quantified with an  estimated  score between 0-
100 with 0 being no methylation and 100 
represents complete methylation for all of the 
CpG dinucleotide in the region. The threshold in 




Total cell lysates were prepared using RIPA 
buffer and proteins were separated on a 4 - 15 % 
SDS-PAGE gel under denaturing conditions. 
Proteins were then transferred to PVDF 
membrane, blocked and probed for specific 
proteins using antibodies: Septin 9 (1: 1000, 
Novus Biologicals, USA); Actin (1:2000, Cell 
Signaling Technology, USA); Rho A (1: 500, Cell 
Signaling Technology, USA). The membranes 
were then incubated with secondary antibodies 
conjugated with horseradish peroxidase followed 
by chemiluminescence substrate based 
development (Super Signal West Dura, Pierce 
Biotechnology, USA).  
 
Cell proliferation assays 
 
Cell proliferation assays were performed using 
Alamar Blue assay (Invitrogen, USA) [11]. Briefly, 
control or overexpressing cells (1 × 104 per well) 
were seeded in a 96-well plate and after 16 h, 50 
µL of Alamar reagent (1 mg/mL) was added and 
incubated for 2 h. Change in Alamar blue 
oxidation is noted as a measure of cell density.  
These values were noted at different time points 
as indicated.  Optical density values were noted 
at 570 nm using a Microplate reader and 
proliferation trend over time was plotted. 
 
Cell migration assays 
 
Cell migrations assays were performed using a 
chemotaxis chamber (NeuroProbe, Gaithersburg, 
MD) [13]. Briefly, cells were seeded in the upper 
chemotaxis chamber and allowed to migrate for 
24 h. After scraping the non-migrated cells from 
the top side, the cells that are migrated to the 
bottom side were stained using Diff-Quik Stain 
Set (Dade Behring, Eschborn, Germany) and 
quantified.  At least five independent fields were 




Tissue sections were deparaffinized with xylene 
and gradient ethanol washes, rehydrated, and 
antigen retrieved in sodium citrate buffer (pH 
6.0). Tissue sections were then blocked with 5 % 
BSA and 0.2 % goat serum. Primary antibodies 
specific to septin 9 (Novus Biologicals, USA) 
were incubated (1:50 v/v), followed by secondary 
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For overexpression, the coding DNA sequence of 
septin 9_v 1 isoform was cloned into pcDNA3.1 
and transfected into cells. Stable cells were 





For cell-based experiments, cells were treated 
with cisplatin (5 M) 24 h and evaluated for 
apoptosis by TUNEL assay. For mouse 
experiments, BALB/c (nu/nu) mice were 
inoculated with SW480 or LoVo cells  (2.5 X 106 
per mouse)  subcutaneously and administered 
with cisplatin (5 M/mouse) intraperitoneally (i.p.) 
on days 3, 6, 10, 14, 20. As the mice used in the 
study ranged in similar weight we used a same 
dose (5 M/mouse) of injection. Tumor size was 
shown as long diameter time short diameter 
(mm2). All mouse experiments were performed 
with prior approval from the institute’s animal 
care committee at The People’s Hospital of 
Laiwu City, Laiwu, Shangdong (protocol no: 
251216).  Housing and all procedures using 
animals were performed in accordance with the 
Animals (Scientific Procedures) Act, 1986 (UK) 
(amended 2013) and reported as per the 
ARRIVE Guidelines for reporting animal research 
[14]. All mice were housed in individually 
ventilated cages (5 per cage) under specific 
pathogen-free (SPF) condition, temperature-
controlled, and in a 12 h/12 h light/dark cycle. 
Animal weights were routinely monitored every 
other day. 
 
Detection of apoptosis 
 
Apoptosis was detected using a TUNEL 
staining kit (Promega, WI) [15]. TUNEL 
staining was performed directly in cells and 
an absolute number of TUNEL positive cells 





RhoA activity in cell lysates was measured 
using Rho-binding pull-down assay as per 
the manufacturer’s instructions (EMD 
Millipore, Germany). The ratio of guanosine 
triphosphate (GTP-bound) to total Rho was 





Data were analyzed using one-way ANOVA with 
statistical significance defined as p < 0.05. All 
analyses were performed using GraphPad Prism 
(version 6) and all values are listed as mean ± 




Septin 9 expression in colon cancer tissues 
and cell lines 
 
To begin with, we evaluated the expression of 
septin 9 in primary colon cancer tissues with their 
corresponding adjacent normal tissue regions as 
respective controls. The results as evaluated 
through immunostaining showed an absence or 
decreased expression of septin 9 in tumor 
tissues as compared to normal regions (Figure 
1A). In addition, septin 9 mRNA analysis using 
PCR showed a similar decrease in septin 9 
expressions in tumor tissues (~58 %; p < 0.001) 
(Figure 1B). While, these results confirmed the 
septin 9 decrease in tumor samples, CRC cell 
lines showed a varied expression profile for 
Septin 9 in different cell lines. Our results in CRC 
lines as evaluated through septin 9 specific PCR 
showed that maximum decrease was seen in the 
most invasive cell line such as SW480 and LoVo 
cells (~50 %; p < 0.01) while in other cell lines 
tested septin 9 mRNA were reduced but to 
varying levels (Figure 1C). 
 
Septin 9 hypermethylation causes reduced 
expression in tumor tissues and cell lines 
 
To determine whether methylation status of the 
septin 9 promoter is involved in the decreased 
expression of septin 9 in tumor tissues and cell 
lines, we first evaluated the promoter methylation 
using a pyrosequencing assay targeting the 
promoter region of septin 9. The results showed 
an increased methylation in the septin 9 
promoter region in tumor tissues compared to the 
adjacent normal tissues (> 3fold; p < 0.01) 
(Figure 2A). Similarly, SW480 and LoVo cells 
exhibited hypermethylation in the promoter 
regions, compared to other cell lines (> 2.5 fold; 
p < 0.01). In addition, 5-AZA (5-aza-2'-
deoxycytidine), a demethylation agent, 
treatments of SW480 and LoVo cells increased 
septin 9 expression (Figure 2C). These results 
together indicate that hypermethylation of septin 
9 promoter regions negatively regulates septin 9 
expression.  
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Figure 1: Septin 9 expression in colon cancer patient samples and cell line 
(A) Septin 9 expression levels were evaluated by immunostaining in primary tissue samples. Representative 
cases are shown (40X). Normal colon cells exhibited expression of septin 9, while it is minimal or absent in 
carcinoma samples. Scale bar 5 µM. (B) Septin 9 mRNA expression profiles in patient samples. Expression 
levels from all the 25 CRC region specimens and matched normal colon region specimens were quantified by 
qRT-PCR. Septin 9 expression was significantly reduced in cancerous regions as compared to normal regions 
(8.1 ± 0.95 fold in normal regions versus 3.4 ± 1.72 in cancer, * p < 0.001). (C) Septin 9 mRNA expression 
profiles in CRC cell lines. SW480 and LoVo cells showed a significant reduction compared to normal cells (CCD-




Figure 2: DNA methylation status inversely correlates with loss of septin 9 expression in CRCs. 
(A).The septin 9 promoter regions are highly methylated in CRC patients as opposed to normal colon 
regions (*p < 0.001). (B) SW480 and LoVo cell lines exhibited the high methylation in promoter 
regions of septin 9, whereas the HT-29 and CCD-18Co (normal) cells showed minimal promoter 
methylation.(*p < 0.01) (C) 5-AZA treatments in SW480 and LoVo cell lines led to significantly 
increased septin 9 levels. Values were normalized against baseline expression in CCD-18Co cells (*p 
< 0.01) 
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Septin 9 suppresses colorectal cancer 
migration, but not proliferation in vitro 
 
To understand the consequence of 
hypermethylation induced decreased septin 9 
expressions in cancer progression, we 
constitutively overexpressed the septin 9 in 
SW480 cells and LoVo cells (~ 50 % reduced; p 
< 0.01) (Figure 3A) and evaluated their 
proliferation and migration. The result showed 
that septin 9 overexpression significantly 
decreased migration for both the cell types with 
septin 9 overexpression, while no significant 
change in their cell proliferation rate in vitro 
(Figure 3B and Figure3C) were noted. In 
addition, as septin 9 is modulating migration in 
both the cell types, which is usually regulated by 
GTPases, we chose to evaluate for changes in 
Rho A. The results showed that septin 9 
overexpression significantly decreased the Rho 
A activation pathway as determined by reduced 
RhoA-GTP levels as compared to total Rho A 
levels (~ 80 % reduced; p < 0.01). These results 
suggest that septin 9 suppresses cell migration 




Figure 3: Septin 9 overexpression correlates with decreased migration but not proliferation 
(A) Stable cells of both SW480 and LoVo cells overexpressing septin 9 were prepared. Immunoblot of septin 9 
and actin was shown. (B)  Alamar blue assay showing no change in proliferation with overexpressing septin 9. 
(C) Decrease in migration were noted in both SW480 and LoVo cells upon overexpressing septin 9 or with 5-AZA 




Figure 4: Septin 9 expression levels are associated with altered RhoA signaling. 
 Increased Rho-GTP was present in SWSW480 cells and LoVo cells, and is reduced with overexpression of 
septin 9 or 5-AZA treatments (~ 80 % reduced; p < 0.01). Representative immunoblots are shown 
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Figure 5: Septin 9 might contribute to drug-induced apoptosis in vitro and in vivo  
(A) SW480 cells and LoVo cells with or without overexpression of septin 9 were treated with cisplatin (5 μM) and 
evaluated for apoptosis. TUNEL positive staining was quantified. Overexpression of septin 9 enhances apoptosis 
(*P < 0.05) (B) Xenograft models of SW480 and LoVo cells with or without septin 9 overexpression were 
established and treated with cisplatin. Changes in tumor size were measured over time. Septin overexpression 
enhanced the effect of cisplatin-induced reduction in tumor size in both cell types from third week onwards (* P < 
0.01) 
 
Septin 9 expressions contribute to drug-
induced apoptosis in vitro and in vivo 
 
We evaluated the efficacy of cisplatin in SW480 
and LoVo CRC cells with the over-expression of 
septin 9. The results showed an increased drug-
induced apoptosis as measured by TUNEL 
assay in overexpressing cells than control cells 
(> 2 fold enhanced; p < 0.05) (Figure 5A). In 
addition, overexpression of septin 9 significantly 
enhanced the drug efficiency in a xenograft 
tumor model (~ 2 fold enhanced; p < 0.01). 
These increased efficiencies were correlating 
with increased TUNEL positive cells in septin 9 




It is well established now that DNA methylation in 
the genome could modulate gene expression 
[16]. In particular, multiple CpG-rich promoter 
regions were extensively studied over the last 
decade and associated the methylation content 
with effect on transcription [17,18]. Similar hyper-
methylation content was also previously 
identified in promoter regions of septin 9 and 
implicated for modulating expression in breast 
cancer cells [19].  In the current study, we 
observed that septin 9 expressions in tissues 
correlate with methylation content in the 
promoter regions in CRC patient samples. This 
notion is further supported by the decreased 
septin 9 expressions in colon cancer cells that 
are hypermethylated in promoter regions. In 
addition, we have shown that demethylation 
treatment restored at least partially the 
expression levels of septin 9, thereby suggesting 
that expression regulation in tumor conditions is 
achieved by aberrant mode of epigenetic 
modifications. 
 
Since septin 9 is involved in modulating 
cytoskeleton [20], it is conceivable that 
suppression of septin 9 could modulate multiple 
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related processes. In accordance with this 
notion, other studies have also shown a function 
of septin 9 in multiple processes such as 
migration and cilia formation. Our data have 
shown that suppressed septin 9 expression 
facilitate migration and altered Rho A signaling, 
while proliferation remains unaffected. This 
suggests that septin 9 functions are context-
dependent, and identification of other binding 
proteins or other means of context could aid us 
to understand septin 9 mediated effects in these 
processes further.  
  
Multiple studies have highlighted increased 
resistance to chemotherapy in advanced CRC 
patients [21,22]. Given that septin 9 suppression 
is one of the early biomarker and prerequisite for 
CRC progression, we reasoned, if this would 
facilitate the development of chemoresistance in 
later stages. Our data have shown that septin 9 
overexpression in cells increases efficiency in 
drug-induced apoptosis. While the specific 
molecular mechanism through which septin 9 
modulates drug efficiency needs further 
investigation, similar proteins such as septin 4 
effects in hepatocellular carcinoma suggests the 
involvement of increased expression of p21 and 
decrease in pro- caspases such as pro-caspase 
7 and 3 [23].  
 
Together, our data indicate that septin 9 plays a 
role in tumor suppression and the particular 
mode of its regulation such as hypermethylation 
affects its expression and related functions. 
However, it also worth mentioning that some of 
the earlier evidence have highlighted oncogenic 
function for septin 9 in breast cancer cells and 
attributed it to the different isoforms of septin 9 
expression and localization. An intriguing 
question raised by our study in the context of 
these data is, how septin 9 hypermethylation 
contributes to variations in isoform expression in 
colon tissues, and how the different isoforms 
would affect CRC progression. While we have 
limited our analysis to septin 9_v1 isoform, future 
studies aimed at understanding these different 
isoform expression patterns in colon tissues and 
its relation to hypermethylation content and 
chemoresistance would provide more insights 




The findings of this study provide the first set of 
evidence for hypermethylation-induced reduction 
of septin 9 expression, which facilitates the 
migration and invasion of CRC cells and 
development of chemoresistance.  Thus, 
chemotherapy options with concurrent 
treatments to increase septin 9 expression may 
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